Population characteristics
| Characteristic . | TCI low (n = 1663)∗ . |
|---|---|
| Age, median (interquartile range), y | 61 (55-66) |
| KPS, n (%) | |
| ≥90 | 1150 (69) |
| <90 | 513 (31) |
| Disease risk (disease risk stratification system), n (%) | |
| Low | 665 (40) |
| Intermediate-1 | 332 (20) |
| Intermediate-2/high | 666 (40) |
| Cytogenetic risk, n (%)† | |
| Favorable | 48 (4) |
| Intermediate | 1003 (73) |
| Poor | 314 (23) |
| Secondary AML, n (%) | 80 (5) |
| Donor, n (%) | |
| Matched sibling donor | 744 (45) |
| Matched unrelated donor | 919 (55) |
| Sex match, n (%) | |
| Other | 1367 (82) |
| Female-to-male | 296 (18) |
| Cytomegalovirus serostatus, n (%) | |
| D−/R− | 371 (22) |
| D−/R+ | 411 (25) |
| D+/R− | 162 (10) |
| D+/R+ | 719 (43) |
| HCT-CI, n (%) | |
| 0 | 713 (43) |
| 1-2 | 434 (26) |
| ≥3 | 516 (31) |
| Regimen, n (%) | |
| Flu + Bu | 1129 (68) |
| Bu + cyclophosphamide | 20 (1) |
| Flu + melphalan | 27 (2) |
| Flu + total body irradiation | 364 (22) |
| Flu + treosulfan | 65 (4) |
| Flu + Bu + thiotepa | 58 (3) |
| Graft-versus-host disease prophylaxis, n (%) | |
| Calcineurin inhibitor + methotrexate | 547 (33) |
| Calcineurin inhibitor + mycophenolate mofetil | 732 (44) |
| Cyclosporine A only | 272 (16) |
| Other/unknown | 111 (7) |
| T-cell depletion, n (%)‡ | |
| None | 610 (37) |
| Alemtuzumab | 113 (7) |
| Antithymocyte globulin | 879 (53) |
| PTCy | 58 (3) |
| Characteristic . | TCI low (n = 1663)∗ . |
|---|---|
| Age, median (interquartile range), y | 61 (55-66) |
| KPS, n (%) | |
| ≥90 | 1150 (69) |
| <90 | 513 (31) |
| Disease risk (disease risk stratification system), n (%) | |
| Low | 665 (40) |
| Intermediate-1 | 332 (20) |
| Intermediate-2/high | 666 (40) |
| Cytogenetic risk, n (%)† | |
| Favorable | 48 (4) |
| Intermediate | 1003 (73) |
| Poor | 314 (23) |
| Secondary AML, n (%) | 80 (5) |
| Donor, n (%) | |
| Matched sibling donor | 744 (45) |
| Matched unrelated donor | 919 (55) |
| Sex match, n (%) | |
| Other | 1367 (82) |
| Female-to-male | 296 (18) |
| Cytomegalovirus serostatus, n (%) | |
| D−/R− | 371 (22) |
| D−/R+ | 411 (25) |
| D+/R− | 162 (10) |
| D+/R+ | 719 (43) |
| HCT-CI, n (%) | |
| 0 | 713 (43) |
| 1-2 | 434 (26) |
| ≥3 | 516 (31) |
| Regimen, n (%) | |
| Flu + Bu | 1129 (68) |
| Bu + cyclophosphamide | 20 (1) |
| Flu + melphalan | 27 (2) |
| Flu + total body irradiation | 364 (22) |
| Flu + treosulfan | 65 (4) |
| Flu + Bu + thiotepa | 58 (3) |
| Graft-versus-host disease prophylaxis, n (%) | |
| Calcineurin inhibitor + methotrexate | 547 (33) |
| Calcineurin inhibitor + mycophenolate mofetil | 732 (44) |
| Cyclosporine A only | 272 (16) |
| Other/unknown | 111 (7) |
| T-cell depletion, n (%)‡ | |
| None | 610 (37) |
| Alemtuzumab | 113 (7) |
| Antithymocyte globulin | 879 (53) |
| PTCy | 58 (3) |
Bu, busulfan; D, donor; Flu, fludarabine; KPS, Karnofsky performance status; PTCy, posttransplantation cyclophosphamide; R, recipient.
Data presented as median (interquartile range) or n (%) as shown.
Per Medical Research Council schema. Missing for 298 patients.
11 patients received PTCy + antithymocyte globulin and 1 received PTCy + alemtuzumab; these are listed as PTCy-based. T-cell depletion status is unknown for 3 patients.